Press Releases

First Previous Next End

July 23, 2014

Provectus Biopharmaceuticals' PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at European Society for Medical Oncology 2014 Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), will have clinical data on PV-10 presented at the European Society for Medical Oncology's 2014 Congress in Madrid, Spain.

July 8, 2014

Provectus Updates Shareholders in Its Annual CEO Letter

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), provides shareholders with an update on its corporate accomplishments, clinical progress and business development efforts during 2013, and shares as well as insights on upcoming plans and milestones for 2014.

June 19, 2014

Provectus Biopharmaceuticals, Inc. to Hold Conference Call Today to Detail Outline of Phase 3 Clinical Trial of PV-10 in Melanoma Treatment

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), wishes to remind interested parties that it will hold a conference call today, Thursday, June 19, 2014 at 4:00 p.m. EDT.

June 12, 2014

Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time.

June 3, 2014

PV-10 Data Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Defines Path Forward for Provectus Biopharmaceuticals, Inc.

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

May 27, 2014

Provectus Biopharmaceuticals Inc. to Hold Conference Call Tuesday, June 3, 2014

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it will hold a conference call on Tuesday, June 3, 2014 at 8:30 a.m. EDT.

May 23, 2014

Provectus Biopharmaceuticals Inc. Reaffirms Its Commitment to Bringing PV-10 to Market Notwithstanding FDA Decision on Breakthrough Therapy Designation

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received notification from the United States Food and Drug Administration that the data upon which the Company based its request for designation of PV-10 as a Breakthrough Therapy for the treatment of patients with locally advanced cutaneous melanoma was insufficient to demonstrate substantial improvement over existing therapies. As a result, the FDA has declined to designate PV-10 as a Breakthrough Therapy at this time. Further data may cause the Agency to revisit this decision at a later date. PV-10 is the Company's novel investigational drug for solid tumors.

May 21, 2014

Provectus Biopharmaceuticals, Inc. Refutes Inaccuracies in Seeking Alpha Article

KNOXVILLE, Tenn.--(BUSINESS WIRE)--It has come to the attention of Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com) that an article was published on seekingalpha.com on May 21, 2104, which contains numerous inaccuracies and misstatements about the Company.

May 21, 2014

Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (PVCT)www.pvct.com), announced today that it has appointed Jacob M. Plotsker to its strategic advisory board.

May 19, 2014

Provectus Biopharmaceuticals to Celebrate NYSE MKT Listing with Opening Bell Ceremony

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (PVCT)www.pvct.com), announced today that its CEO and Chairman Dr. Craig Dees, PhD, its CTO Dr. Eric Wachter, PhD and its CFO and COO Peter Culpepper, along with Alfred E. Smith, IV, Lead Independent Director of its Board, along with key advisors will ring The Opening Bell® at the New York Stock Exchange at 9:30 a.m. EDT on Thursday, May 22, 2014.

May 16, 2014

Provectus Biopharmaceuticals Inc.'s Common Shares to Begin Trading on NYSE MKT

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced that its shares will begin trading on the NYSE MKT today Friday May 16, 2014.

May 15, 2014

Provectus Biopharmaceuticals' PV-10 Data Show Exceptional Complete Response Rates in Refractory Melanoma Patients

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma will be featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting to be held at McCormick Place, Chicago, IL.

May 14, 2014

Provectus Biopharmaceuticals' PV-10 Data Show Exceptional Complete Response Rates in Refractory Melanoma Patients

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma will be featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting to be held at McCormick Place, Chicago, IL.

May 13, 2014

Provectus Biopharmaceuticals Inc. to List on NYSE MKT

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that its shares of common stock have been approved for listing on the NYSE MKT. Shares will begin trading on the NYSE MKT on Friday May 16, 2014.

May 6, 2014

Provectus Biopharmaceuticals Inc. Appoints Brendan O'Brien to Strategic Advisory Board

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that it has appointed Brendan O'Brien to its strategic advisory board.

April 28, 2014

Provectus Biopharmaceuticals Inc. Retains Roberti+White, LLC as Public Policy Consultants

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that it has retained the services of Roberti+White, LLC as its public policy consultants.

April 21, 2014

Provectus' PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at 10th European Association of Dermato-Oncology Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that Dr. Sanjiv Agarwala of St. Luke's University Health Network will present clinical data on Provectus' PV-10 preparation for the treatment of melanoma at the 10th European Association of Dermato-Oncology (EADO) Congress in Vilnius, Lithuania.

April 14, 2014

Provectus Biopharmaceuticals Signs Agreement with China's Tririver Capital

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that it has entered into an advisory agreement with China's Tririver Capital to help identify distribution and joint venture partners for the Company's novel oncology drug PV-10 in China, as well as other therapeutics that Provectus is developing.

April 7, 2014

Induction of Systemic Immunity Following Treatment of Tumors with PV-10 Reported by Moffitt Cancer Center Researchers at American Association for Cancer Research Annual Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that a poster presentation detailing significant decrease in melanoma cells in patients' injected tumors 7-14 days after intralesional PV-10 treatment that was accompanied by similar decrease in uninjected bystander tumors was presented April 6 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in San Diego, CA.

April 2, 2014

Provectus Biopharmaceuticals' PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at the American Society of Clinical Oncology (ASCO) Annual Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that data on its investigational drug PV-10 will be featured in a presentation by investigators from Moffitt Cancer Center in a Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL, May 30-June 3, 2014.

First Previous Next End